Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies

被引：0
|
作者：
Simpson, Eric L. [1 ]
Kircik, Leon [2 ]
Blauvelt, Andrew [3 ]
Kuligowski, Michael E. [4 ]
Venturanza, May E. [4 ]
Sun, Kang [4 ]
Eichenfield, Lawrence F. [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Oregon Med Res Ctr, Tigard, OR USA
[4] Incyte Corp, Wilmington, DE USA
[5] Univ Calif San Diego, San Diego, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27620
引用
收藏
页码：AB157 / AB157
页数：1
相关论文
共 50 条
  • [21] Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
    Lisa Bloudek
    Lawrence F. Eichenfield
    Jonathan I. Silverberg
    Vijay N. Joish
    Jennifer H. Lofland
    Kang Sun
    Matthias Augustin
    Kristen Migliaccio-Walle
    Sean D. Sullivan
    American Journal of Clinical Dermatology, 2023, 24 : 109 - 117
  • [22] The Self-Administered Eczema Area and Severity Index in Children with Moderate to Severe Atopic Dermatitis: Better Estimation of AD Body Surface Area Than Severity
    van Velsen, Sara G. A.
    Knol, Miriam J.
    Haeck, Inge M.
    Bruijnzeel-Koomen, Carla A. F. M.
    Pasmans, Suzanne G. M. A.
    PEDIATRIC DERMATOLOGY, 2010, 27 (05) : 470 - 475
  • [23] Product of Investigator Global Assessment and body surface area: a practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children
    Suh, T. P.
    Ramachandran, D.
    Patel, V.
    Jackson, K. L.
    Rangel, S. M.
    Fishbein, A. B.
    Paller, A. S.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E118 - E119
  • [24] Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
    Papp, Kim
    Szepietowski, Jacek C.
    Kircik, Leon
    Toth, Darryl
    Eichenfield, Lawrence F.
    Forman, Seth B.
    Kuligowski, Michael E.
    Kallender, Howard
    Sun, Kang
    Ren, Haobo
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (05) : 1008 - 1016
  • [25] Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies
    Papp, K.
    Szepietowski, J.
    Kircik, L.
    Toth, D.
    Eichenfield, L.
    Forman, S.
    Kuligowski, M.
    Venturanza, M.
    Sun, K.
    Simpson, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S184 - S184
  • [26] Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
    Thyssen, Jacob P.
    de Bruin-Weller, Marjolein
    Costanzo, Antonio
    Grond, Susanne
    Schuster, Christopher
    Liu, Chunyuan
    Rueda, Maria Jose
    Chen, Yun-Fei
    Pinter, Andreas
    Bieber, Thomas
    ADVANCES IN THERAPY, 2023, 40 (08) : 3574 - 3587
  • [27] Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
    Jacob P. Thyssen
    Marjolein de Bruin-Weller
    Antonio Costanzo
    Susanne Grond
    Christopher Schuster
    Chunyuan Liu
    Maria Jose Rueda
    Yun-Fei Chen
    Andreas Pinter
    Thomas Bieber
    Advances in Therapy, 2023, 40 : 3574 - 3587
  • [28] Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
    Eichenfield, Lawrence F.
    Simpson, Eric L.
    Papp, Kim
    Szepietowski, Jacek C.
    Blauvelt, Andrew
    Kircik, Leon
    Silverberg, Jonathan I.
    Siegfried, Elaine C.
    Kuligowski, Michael E.
    Venturanza, May E.
    Kallender, Howard
    Ren, Haobo
    Paller, Amy S.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (04) : 669 - 683
  • [29] Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children
    Suh, Timothy P.
    Ramachandran, Divya
    Patel, Vidhi
    Jackson, Kathryn L.
    Rangel, Stephanie M.
    Fishbein, Anna B.
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (05) : 1187 - 1194
  • [30] Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme
    Barbier, N
    Paul, C
    Luger, T
    Allen, R
    De Prost, Y
    Papp, K
    Eichenfield, LF
    Cherill, R
    Hanifin, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (01) : 96 - 102
12345